KR102129412B1 - Composition for preventing, improving or treating benign prostatic hyperplasia - Google Patents
Composition for preventing, improving or treating benign prostatic hyperplasia Download PDFInfo
- Publication number
- KR102129412B1 KR102129412B1 KR1020180006423A KR20180006423A KR102129412B1 KR 102129412 B1 KR102129412 B1 KR 102129412B1 KR 1020180006423 A KR1020180006423 A KR 1020180006423A KR 20180006423 A KR20180006423 A KR 20180006423A KR 102129412 B1 KR102129412 B1 KR 102129412B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- present
- astragalus
- broiler
- pharmaceutical composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims abstract description 35
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title claims abstract description 34
- 239000000284 extract Substances 0.000 claims abstract description 58
- 241000287828 Gallus gallus Species 0.000 claims abstract description 51
- 210000002307 prostate Anatomy 0.000 claims abstract description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 29
- 235000013305 food Nutrition 0.000 claims abstract description 28
- 235000019206 astragalus extract Nutrition 0.000 claims abstract description 26
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 230000002265 prevention Effects 0.000 claims abstract description 11
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 235000006533 astragalus Nutrition 0.000 claims description 30
- 241001061264 Astragalus Species 0.000 claims description 23
- 210000004233 talus Anatomy 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000002904 solvent Substances 0.000 claims description 16
- 208000024891 symptom Diseases 0.000 claims description 14
- 210000002700 urine Anatomy 0.000 claims description 14
- 230000027939 micturition Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 241000045403 Astragalus propinquus Species 0.000 claims description 6
- 210000001635 urinary tract Anatomy 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 206010013990 dysuria Diseases 0.000 claims description 4
- 241000723347 Cinnamomum Species 0.000 claims description 3
- 206010046555 Urinary retention Diseases 0.000 claims description 3
- 230000003187 abdominal effect Effects 0.000 claims description 3
- 230000003111 delayed effect Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000008719 thickening Effects 0.000 claims description 3
- 208000008967 Enuresis Diseases 0.000 claims description 2
- 208000004880 Polyuria Diseases 0.000 claims description 2
- 206010046543 Urinary incontinence Diseases 0.000 claims description 2
- 206010046459 urethral obstruction Diseases 0.000 claims description 2
- 230000003313 weakening effect Effects 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 abstract description 12
- 230000006872 improvement Effects 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000000605 extraction Methods 0.000 description 15
- 239000013642 negative control Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 244000037364 Cinnamomum aromaticum Species 0.000 description 4
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 4
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- -1 troches Substances 0.000 description 4
- 210000003708 urethra Anatomy 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000605072 Cinnamomum verum Species 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000001934 delay Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 235000021512 Cinnamomum verum Nutrition 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 239000008989 cinnamomi cortex Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 206010029446 nocturia Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000266855 Astragalus mongholicus Species 0.000 description 1
- 241000790026 Astragalus uliginosus Species 0.000 description 1
- 206010005052 Bladder irritation Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 244000037185 Cinnamomum burmannii Species 0.000 description 1
- 235000014487 Cinnamomum burmannii Nutrition 0.000 description 1
- 241000252804 Cinnamomum insularimontanum Species 0.000 description 1
- 235000002428 Cinnamomum japonicum Nutrition 0.000 description 1
- 241001350919 Cinnamomum loureiroi Species 0.000 description 1
- 241000107513 Cinnamomum subavenium Species 0.000 description 1
- 241000917739 Cinnamomum wilsonii Species 0.000 description 1
- 235000004310 Cinnamomum zeylanicum Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- GGLIEWRLXDLBBF-UHFFFAOYSA-N Dulcin Chemical compound CCOC1=CC=C(NC(N)=O)C=C1 GGLIEWRLXDLBBF-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 208000021473 Ejaculation disease Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010051482 Prostatomegaly Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010038967 Retrograde ejaculation Diseases 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- 208000028938 Urination disease Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960004607 alfuzosin Drugs 0.000 description 1
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- PARMADWNFXEEFC-UHFFFAOYSA-N bamethan sulfate Chemical compound [O-]S([O-])(=O)=O.CCCC[NH2+]CC(O)C1=CC=C(O)C=C1.CCCC[NH2+]CC(O)C1=CC=C(O)C=C1 PARMADWNFXEEFC-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000443 biocontrol Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000013844 butane Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 239000008126 dulcin Substances 0.000 description 1
- NWNUTSZTAUGIGA-UHFFFAOYSA-N dulcin Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(O)CC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NWNUTSZTAUGIGA-UHFFFAOYSA-N 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000011224 negative regulation of urine volume Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000001120 potassium sulphate Substances 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 210000000064 prostate epithelial cell Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229960004953 silodosin Drugs 0.000 description 1
- PNCPYILNMDWPEY-QGZVFWFLSA-N silodosin Chemical compound N([C@@H](CC=1C=C(C=2N(CCCO)CCC=2C=1)C(N)=O)C)CCOC1=CC=CC=C1OCC(F)(F)F PNCPYILNMDWPEY-QGZVFWFLSA-N 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960002613 tamsulosin Drugs 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 육계 추출물 및 황기 추출물을 유효성분으로 포함하는 약제학적 조성물 및 식품 조성물에 대한 것이다. 본 발명의 조성물은 전립선 비대증에서, 전립선 조직이 커지는 것을 억제하고, 5α-리덕타아제의 발현을 억제하므로 전립선 비대증의 예방, 치료 및 개선용으로 사용될 수 있다.The present invention relates to a pharmaceutical composition and a food composition comprising a broiler extract and astragalus extract as active ingredients. The composition of the present invention can be used for the prevention, treatment and improvement of prostatic hyperplasia in prostate hyperplasia, inhibiting the growth of prostate tissue and inhibiting the expression of 5α-reductase.
Description
본 발명은 전립선 비대증의 예방, 개선 또는 치료용 약제학적 조성물 및 식품 조성물에 대한 것이다.The present invention relates to a pharmaceutical composition and a food composition for preventing, improving or treating prostatic hyperplasia.
전립선은 남성에서 요도가 시작되는 주위를 둘러싸고 있고, 방광의 아래에 있는 점액성 물질을 생성하는 호두모양의 기관이다. 전립선의 유일한 기능은 번식을 위하여, 정자를 보호하고 활발하게 하는 정액을 생성하는 것이다. 전립선은 나이가 들면서 자라고 커지는 특성을 갖고 있으며, 대부분의 포유동물들은 방광으로부터 소변을 배출하는 통로인 요도가 전립선을 통과하는 특성을 가지고 있다. 이러한 전립선의 해부학적 특성으로 인해 남성에게는 나이가 들어갈수록 소변 배출과 관련된 문제가 종종 초래될 수 있으며, 전립선 관련 질환을 포함한 각종 질환이 유발되기도 한다.The prostate is a walnut-shaped organ that surrounds the urethra in men and produces a mucous substance under the bladder. The only function of the prostate is to produce sperm that protects and activates sperm for reproduction. The prostate gland grows and grows with age, and most mammals have the characteristic that the urethra, a passage for urine discharge from the bladder, passes through the prostate. Due to the anatomical characteristics of the prostate gland, problems related to urine discharge may often occur in men as they age, and various diseases including prostate related diseases may also be caused.
전립선 비대증은 과거에는 전립선이 비대해져 방광 하부의 소변이 나오는 통로를 막아 요도 폐색을 일으켜 소변의 흐름이 감소된 상태로 정의하였고, 조직학적으로는 전립선 간질이나 전립선의 상피조직 세포가 증식된 것으로 정의되었으나, 최근에는 이와 같은 정의나 개념으로 설명하기에는 질병의 병태 생리가 너무 복잡하여, 현재 '50세 이상의 남성에서 하루 8회 이상 소변을 보는 빈뇨, 야간 빈뇨, 강하고 갑작스런 요의(오줌이 마려운 느낌)를 느끼면서 소변이 마려우면 참을 수 없는 절박뇨, 절박요실금, 야간 빈뇨, 배뇨통 등의 방광 저장 장애 증상과 지연뇨(소변을 볼 때 뜸을 들여야 소변이 나오는 현상), 단절뇨(소변의 흐름이 끊기는 현상), 복압배뇨(배뇨 시 힘을 주어야 하는 현상), 요선약화, 배뇨감, 요폐 등의 방광의 배출 장애 증상을 통칭한 하부 요로증상(Lower Urinary Tract Symptoms, LUTS)을 나타내는 것을 전립선 비대증으로 정의하고 있다. Prostate hyperplasia was defined as a condition in which the flow of urine was reduced by blocking the passage of urine from the lower part of the bladder and causing a decrease in urine flow, and histologically defined as prostate epilepsy or prostate epithelial cell proliferation. , In recent years, the pathophysiology of the disease is too complex to explain with this definition or concept, and currently, in men over 50, urinating urine more than 8 times a day, nocturia at night, strong urgent urinary tract (feeling of urinary irritation) Bladder storage disorder symptoms such as unbearable urgency, urge incontinence, nocturia, urination pain, delayed urination (the urine should be given when you look at the urine, and urine comes out when you feel urine); ), abdominal pressure urination (a phenomenon that should give strength during urination), low urinary tract symptoms (LUTS), which collectively refer to symptoms of dysfunction of the bladder, such as weakening of the urine, urination, and urinary tract, are defined as prostatic hyperplasia. have.
이와 같은 전립선 비대증의 큰 원인 중 하나는 전립선 평활근 또는 요도 평활근의 수축과 이완의 불균형에 의해 발생하며, 가장 큰 유발인자로는 연령증가와 남성호르몬의 존재이다. 그 외에 인종과 환경, 식생활, 유전적 요인들도 발병에 영향을 줄 수 있다. 일반적으로 30에서 40대에 시작하여 대개 60세 이후에 증상이 나타나며, 나이가 들어감에 따라 현미경적 비대전립선의 50% 이상이 촉지 가능한 비대전립선으로 발전한다(Prostate 1996 (suppl. 6) 67-73).One of the major causes of prostatic hyperplasia is the contraction and relaxation of prostate smooth muscle or urethral smooth muscle, and the most probable factors are age increase and the presence of male hormones. In addition, race, environment, diet, and genetic factors can also affect the onset. It usually begins in the 30s to 40s and usually develops after 60 years of age, and with age, more than 50% of the microscopic hypertrophy develops into a palpable hypertrophic prostate (Prostate 1996 (suppl. 6) 67-73 ).
전립선 비대증의 진단은 직장 내 전립선 촉진 등에 의해 이루어지며, 방광출구폐색 및 방광자극증상 정도를 요류 역학이나 초음파를 통해 정밀검사를 참고로 하며 이를 바탕으로 적절한 치료방법을 선택한다. Diagnosis of hyperplasia of the prostate is made by promoting the prostate in the rectum, and the degree of bladder exit obstruction and bladder irritation is referred to a precise examination through urine dynamics or ultrasound, and the appropriate treatment method is selected based on this.
현재 전립선 비대증의 치료제로 알파-교감신경 차단제와 5α-리덕타아제 억제제가 많이 사용되고 있다. Currently, alpha-sympathetic blockers and 5α-reductase inhibitors are widely used as a treatment for prostatic hyperplasia.
알파-교감신경 차단제로는 알푸조신(alfuzosin), 테라조신(terazosin), 독사조신(doxazosin), 프라조신(prazosin), 탐술로신(tamsulosin), 실로도신(silodosin) 등이 대표적이며, 이는 전립선 조직 내의 평활근의 긴장도를 감소시켜 폐색증상을 감소시킨다. 그러나 알파-교감신경 차단제는 요도를 직접적으로 확장시켜 배뇨장애를 해결하므로 투약 중단시 원점으로 돌아가는 단점이 있다. 또한 기립성 저혈압을 일으키고 역행사정의 부작용으로 인해 전립선 비대증과 발기부전을 동반한 환자에게 적절한 치료제가 아니다. 또한, 중증 간기능과 신기능 장애 환자에게 신중한 투여가 고려된다. Alpha-sympathetic nerve blockers include alfuzosin, terazosin, doxazosin, prazosin, tamsulosin, silodosin, etc. It reduces the degree of tension of smooth muscles in the tissues, thereby reducing occlusion symptoms. However, the alpha-sympathetic nerve blocker has the disadvantage of returning to the origin when the medication is stopped because it directly resolves urination disorders by directly expanding the urethra. In addition, it is not a suitable treatment for patients with prostate hypertrophy and erectile dysfunction, which cause orthostatic hypotension and side effects of retrograde ejaculation. In addition, careful administration to patients with severe liver and renal impairment is contemplated.
반면, 피나스테라이드(finasteride)와 같은 5α-리덕타아제 억제제는 전립선을 비후시키는 디하이드로테스토스테론(dihydrotestosterone; DHT)을 차단시켜 전립선 조직의 분화를 감소시키고, 그 크기를 감소시킴으로서 장기적으로 요속을 증가시키고 배뇨장애증상을 완화시킨다. 그러나 최소 6개월 이상 장기 복용하여야 약효가 발현되며 발기부전, 성욕감소, 사정장애 및 여성형 유방 등의 부작용이 나타나는 단점이 있다. On the other hand, 5α-reductase inhibitors, such as finasteride, block dihydrotestosterone (DHT), which thickens the prostate, thereby reducing the differentiation of prostate tissue and increasing its urine velocity in the long run by reducing its size and urination. Relieve symptoms of disability. However, the drug has a long-term effect for at least 6 months, and there are disadvantages such as erectile dysfunction, decreased libido, ejaculation disorder, and side effects such as female breast.
또한, 최근 전립선 비대증에 따른 방광기능을 개선하고자 항콜린제가 사용되기도 하나 그 효과 또한 제한적이고 부작용에 대한 우려가 항상 존재하고 있어 이를 개선할 약물의 개발이 절실히 요구되고 있다.In addition, although anticholinergics are used to improve bladder function due to prostate hyperplasia, the effects are also limited and there are always concerns about side effects, so there is an urgent need to develop drugs to improve them.
한편, 육계(Cinnamomi Cortex)는 녹나무과(Lauraceae)에 속하는 육계나무(Cinnamomum cassia) 또는 그밖의 동속 근연식물의 줄기껍질로, 주피를 다소 제거하여 사용하기도 한다. 육계는 통 모양 또는 말려 들어간 통 모양이고, 길이 5 cm 내지 50 cm, 지름 1.5 cm 내지 5 cm, 두께 0.1 cm 내지 0.5 cm이다. 바깥 면은 어두운 적갈색, 안쪽 면은 적갈색을 띠며 매끈하다. 꺾이기 쉬우며 꺾인 면은 적갈색을 띠고 연한 갈색의 얇은 층이 있으며 약간 섬유성이다. On the other hand, broiler (Cinnamomi Cortex) is a stem bark of Cinnamomum cassia or other related plants belonging to the family Lauraceae, and is also used to remove some of the skin. Broilers are tubular or rolled tubular, 5 cm to 50 cm long, 1.5 cm to 5 cm in diameter, and 0.1 cm to 0.5 cm thick. The outer side is dark reddish brown, and the inner side is reddish brown. It is easy to bend and the bent side is reddish brown, has a light brown thin layer and is slightly fibrous.
황기(Astragali Radix)는 콩과(Leguminosae)에 속하는 황기(Astragalus membranaceus) 또는 그밖의 동속 근연식물의 뿌리 부위를 지칭하며, 주피를 벗겨 사용할 때가 많다. 황기는 가늘고 긴 원주형을 이루고 길이 30 cm 내지 100 cm, 지름 7 mm 내지 20 mm 이며, 드문드문 작은 가지뿌리가 붙어있으나 분지되는 일은 없고 근두부 가까이에서는 약간 꼬여지고 줄기의 잔기가 남아있다. 바깥면은 엷은 회황색-엷은 황갈색이며 회갈색의 코르크층이 군데군데 남아 있고 불규칙한 거친 세로의 주룸과 가로로 피목같은 모양이 보인다. 질은 치밀하고 꺾기 힘들며 꺾은 면은 섬유성이다.Astragali Radix refers to the root region of Astragalus membranaceus belonging to the legumes (Leguminosae) or other related plants, and is often peeled off. Astragalus is elongated columnar, 30 cm to 100 cm long, 7 mm to 20 mm in diameter, with sparse small roots attached, but not branched, slightly twisted near the roots and residues of the stem remaining. The outer surface is pale grayish yellow to pale yellowish brown, and there are gray corked layers. The irregular rough vertical main room and horizontal cortical look are seen. The vagina is dense, hard to bend, and the bent side is fibrous.
본 발명의 목적은 전립선 비대증의 예방 또는 치료용 약제학적 조성물을 제공하는 것이다.An object of the present invention is to provide a pharmaceutical composition for preventing or treating prostatic hyperplasia.
본 발명의 다른 목적은 전립선 비대증의 예방 또는 개선용 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition for preventing or improving prostatic hyperplasia.
상기 목적을 달성하기 위하여, 본 발명은 육계 추출물 및 황기 추출물을 유효성분으로 포함하는 전립선 비대증의 예방 또는 치료용 약제학적 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating prostatic hyperplasia, including broiler extract and astragalus extract as active ingredients.
본 발명에서, 육계(Cinnamomi Cortex)는 Cinnamomum cassia 또는 그밖의 동속 근연식물의 줄기껍질을 의미한다. 상기 Cinnamomum cassia 또는 그밖의 동속 근연식물은 구체적으로, Cinnamomum cassia, Cinnamomum loureiroi, Cinnamomum verum, Cinnamomum burmannii, Cinnamomum wilsonii, Cinnamomum chingii, Cinnamomum japonicum, Cinnamomum zeylanicum, Cinnamomum obtusifolim 및 Cinnamomum sieboldii을 들 수 있으나, 이에 한정되는 것은 아니다. 본 발명의 구체적인 구현예에서, 육계는 Cinnamomum verum의 줄기껍질일 수 있다.In the present invention, broiler (Cinnamomi Cortex) refers to the stem bark of Cinnamomum cassia or other related root plants. The Cinnamomum cassia or other related plants are specifically Cinnamomum cassia , Cinnamomum loureiroi , Cinnamomum verum , Cinnamomum burmannii , Cinnamomum wilsonii , Cinnamomum chingii , Cinnamomum japonicum , Cinnamomum zeylanicum , Cinnamomum obtusifolim and Cinnamomum obtusifolim It is not. In a specific embodiment of the present invention, broiler may be the stem bark of Cinnamomum verum .
본 발명에서, 황기(Astragali Radix)는 Astragalus membranaceus 또는 그밖의 동속 근연식물의 뿌리를 의미한다. 상기 Astragalus membranaceus 또는 그밖의 동속 근연식물은 구체적으로, Astragalus mongholicus, Astragalus uliginosus 및 Astragalus membranaceus var. mongholicus를 들 수 있으나, 이에 한정되는 것은 아니다. 본 발명의 구체적인 구현예에서, 황기는 Astragalus membranaceus의 뿌리일 수 있다.In the present invention, astragalus (Astragali Radix) refers to the root of Astragalus membranaceus or other related plants. The Astragalus membranaceus or other related plants are specifically, Astragalus mongholicus , Astragalus uliginosus and Astragalus membranaceus var. mongholicus , but is not limited thereto. In a specific embodiment of the present invention, astragalus may be the root of Astragalus membranaceus .
본 발명에서, 육계 및 황기는 자연 상태 그대로인 것뿐만 아니라, 반건조, 건조 등의 가공된 것을 포함한다.In the present invention, broiler and astragalus include not only the natural state, but also semi-dried and dried.
본 발명에서, 추출물(extract)은 천연물을 추출 처리하여 얻어지는 추출액, 상기 추출액의 분획물, 상기 추출액 또는 분획물의 조정제물이나 정제물, 또는 이들의 희석액, 농축액, 건조물, 또는 이들의 혼합물 등, 육계 및 황기로부터 형성가능한 모든 제형의 추출물을 포함한다.In the present invention, the extract (extract) is an extract obtained by extracting a natural product, a fraction of the extract, a crude or refined product of the extract or fraction, or a dilution, concentrate, dried product, or a mixture thereof, broiler and Contains extracts of all formulations formable from astragalus.
본 발명에서 추출물은 이 분야에 공지된 일반적 제조방법을 사용하여 제조될 수 있으며, 특별히 제한되지 않는다. 예를 들어, 초음파 추출법(sonication extraction), 초임계 추출법(supercritical extraction), 감압 추출법(vacumn extraction), 환류 추출법(reflux extraction), 열수 추출법(hot-water extraction), 고온 가압 추출법(autoclave extraction), 초고압 추출법(high-pressure extraction), 효소 추출법(enzyme extraction), 또는 추출 용매를 사용하여 공지의 방법에 의해 제조하는 방법일 수 있으나, 이에 한정되는 것은 아니다.In the present invention, the extract may be prepared using a general manufacturing method known in the art, and is not particularly limited. For example, ultrasonic extraction, supercritical extraction, vacuum extraction, reflux extraction, hot-water extraction, autoclave extraction, High-pressure extraction (high-pressure extraction), enzyme extraction (enzyme extraction), or may be a method prepared by a known method using an extraction solvent, but is not limited thereto.
본 발명에서, 추출물은 물, 유기용매 또는 이들의 혼합물을 추출 용매로 하여 추출액으로 제조될 수 있다. 상기 물은 예를 들어, 증류수, 정제수, 무균수를 들 수 있으나, 이에 한정되는 것은 아니다. 상기 유기용매는 예를 들어, 알코올, 글리세린, 부틸렌글리콜, 프로필렌글리콜, 메틸아세테이트, 에틸아세테이트, 아세톤, 벤젠, 헥산, 디에틸에테르 및 디클로로메탄를 들 수 있으나, 이에 한정되는 것은 아니다. In the present invention, the extract may be prepared as an extract using water, an organic solvent or a mixture thereof as an extraction solvent. The water may be, for example, distilled water, purified water, sterile water, but is not limited thereto. The organic solvent may include, for example, alcohol, glycerin, butylene glycol, propylene glycol, methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, and dichloromethane, but is not limited thereto.
본 발명에서, 추출물은 바람직하게는 물, 탄소수 1 내지 4의 저가 알코올(메탄올, 에탄올, 프로판올 또는 부탄올) 또는 이들의 혼합물로 이루어진 군에서 선택된 용매를 추출 용매로 하여 추출된 것일 수 있다. 상기 탄소수 1 내지 4의 저가 알코올의 농도는 10 % 내지 90 %일 수 있고, 바람직하게는 20 % 내지 70 % 일 수 있고, 더 바람직하게는 25 % 내지 50 % 일 수 있다. 본 발명의 구체적인 구현예에서, 육계 추출물은 증류수를 추출 용매로 하여 추출된 것일 수 있다. 본 발명의 구체적인 구현예에서, 황기 추출물은 증류수를 추출 용매로 하여 추출된 것일 수 있다.In the present invention, the extract may be extracted by using a solvent selected from the group consisting of water, low-cost alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol or butanol) or a mixture thereof. The concentration of the low alcohol having 1 to 4 carbon atoms may be 10% to 90%, preferably 20% to 70%, and more preferably 25% to 50%. In a specific embodiment of the present invention, the broiler extract may be extracted using distilled water as an extraction solvent. In a specific embodiment of the present invention, the astragalus extract may be extracted using distilled water as an extraction solvent.
본 발명에서, 분획물은 여러 다양한 구성 성분들을 포함하는 혼합물로부터 특정 성분 또는 특정 성분 그룹을 분리하기 위하여 분획을 수행하여 수득된 결과물을 의미한다. 본 발명에서, 분획물은 추출액을 분획하여 제조될 수 있다.In the present invention, a fraction refers to a product obtained by performing a fraction to separate a specific component or a specific component group from a mixture containing various various components. In the present invention, the fraction can be prepared by fractionating the extract.
본 발명에서, 상기 분획물의 제조에 사용되는 분획 용매의 종류는 특별히 제한되지 않으며, 본 기술 분야에서 공지된 임의의 용매를 사용할 수 있다. 상기 분획 용매는 예를 들어, 물, 탄소수 1 내지 4의 알코올, 헥산, 에틸 아세테이트, 클로로포름, 디클로로메탄 또는 이들의 혼합물 등을 들 수 있으나, 이에 한정되는 것은 아니다. 상기 분획 용매는 단독으로 사용되거나 2종 이상을 혼합하여 사용될 수 있으며, 용매의 극성에 따라 순차적으로 사용하여 각 용매의 분획물을 제조할 수 있다.In the present invention, the type of fractional solvent used in the preparation of the fraction is not particularly limited, and any solvent known in the art may be used. The fractional solvent may include, for example, water, alcohol having 1 to 4 carbon atoms, hexane, ethyl acetate, chloroform, dichloromethane, or a mixture thereof, but is not limited thereto. The fractional solvent may be used alone or in combination of two or more, and may be sequentially used according to the polarity of the solvent to prepare fractions of each solvent.
본 발명에서, 정제물은 추출액 또는 분획물에 추가의 정제 과정을 더 수행하여 수득된 결과물을 의미한다. 상기 정제는 이 분야에 공지된 일반적인 방법을 사용할 수 있으며, 예를 들어, 실리카겔 컬럼 크로마토그래피(silica gel column chromatography), 박층 크로마토그래피(thin layer chromatography), 고성능 액체 크로마토그래피(high performance liquid chromatography) 등과 같은 다양한 크로마토그래피를 들 수 있으나, 이에 한정되는 것은 아니다.In the present invention, the purified product means the result obtained by further performing an additional purification process to the extract or fraction. The purification may use a general method known in the art, for example, silica gel column chromatography, thin layer chromatography, high performance liquid chromatography, etc. The same variety of chromatography may be mentioned, but is not limited thereto.
본 발명에서, 추출물은 여과, 농축 또는 건조과정을 수행하여 용매가 제거되거나, 여과, 농축 및 건조를 모두 수행한 것일 수 있다. 상기 여과는 예를 들어, 여과지 또는 감압여과기를 이용할 수 있다. 상기 농축은 예를 들어, 감압 농축기 또는 회전 증발기를 이용할 수 있다. 상기 건조는 예를 들어, 분무건조법 또는 동결건조법으로 수행할 수 있다. In the present invention, the solvent may be removed by performing a filtration, concentration, or drying process, or all of filtration, concentration, and drying. The filtration may be, for example, filter paper or a vacuum filter. The concentration may be, for example, a reduced pressure concentrator or a rotary evaporator. The drying may be performed, for example, by spray drying or freeze drying.
또한, 본 발명에서, 추출물은 사용 시까지 급속 냉동 냉장고(deep freezer)에 보관할 수 있고, 농축 및 동결건조를 통하여 수분을 완전히 제거시킬 수 있으며, 수분을 완전히 제거시킨 추출물은 분말형태로 사용하거나 상기 분말을 증류수 또는 통상의 용매에 녹여 사용할 수 있다.In addition, in the present invention, the extract can be stored in a deep freezer until use, and can be completely removed through concentration and freeze-drying, and the extract that completely removes water is used in powder form or the The powder can be used by dissolving it in distilled water or a conventional solvent.
본 발명에서, 육계 추출물 및 황기 추출물은 육계와 황기를 각각 별도로 추출한 후 혼합한 것, 또는 육계와 황기를 추출 전 혼합하여 추출한 것을 모두 포함한다. 본 발명의 구체적인 구현예에서, 육계 추출물 및 황기 추출물은 육계와 황기를 각각 별도로 추출한 후 혼합한 것일 수 있다. In the present invention, the broiler extract and the astragalus extract include both a broiler and astragalus separately extracted and mixed, or a mixture of a broiler and astragalus before extraction. In a specific embodiment of the present invention, the broiler extract and the astragalus extract may be mixed after separately extracting the broiler and the astragalus.
본 발명에서, "육계 및 황기 복합 추출물"은 육계와 황기를 각각 별도로 추출한 후 혼합한 것, 또는 육계와 황기를 추출 전 혼합하여 추출한 것을 지칭하는 용어로 사용된다.In the present invention, "the broiler and astragalus complex extract" is used as a term referring to a mixture after extracting broiler and astragalus separately, or mixing and extracting broiler and astragalus before extraction.
본 발명의 약제학적 조성물에서, 육계 추출물 및 황기 추출물의 함량비는 1 : 0.5 내지 1 : 100, 바람직하게는 1 : 1 내지 1 : 10 일 수 있다. 본 발명의 구체적인 구현예에서, 육계 추출물 및 황기 추출물의 함량비는 1 : 4 일 수 있다. In the pharmaceutical composition of the present invention, the content ratio of broiler extract and astragalus extract may be 1: 0.5 to 1: 100, preferably 1: 1 to 1: 10. In a specific embodiment of the present invention, the content ratio of broiler extract and astragalus extract may be 1:4.
본 발명에서, 전립선 비대증은 전립선이 비정상적으로 커지면서 요도를 압박해 소변을 보기 힘들게 만드는 질환을 의미한다. 주로 전립선의 크기가 커져 하부요로 증상이 동반될 때 전립선 비대증으로 진단하게 된다. In the present invention, prostatic hyperplasia refers to a disease in which the prostate is abnormally enlarged, and the urethra is compressed to make it difficult to urinate. When the size of the prostate gland is large and accompanied by symptoms of lower urinary tract, it is diagnosed with prostate hyperplasia.
본 발명에서, 전립선 비대증은 구체적으로 전립선 비후, 요도 폐쇄, 배뇨곤란, 다뇨, 야뇨, 요실금, 배뇨통, 지연뇨, 단절뇨, 복압배뇨, 요선약화, 잔뇨감, 요폐 또는 이들의 혼합된 증상을 포함한다.In the present invention, prostatic hyperplasia specifically includes prostate thickening, urethral obstruction, difficulty urinating, polyuria, enuresis, urinary incontinence, urination pain, delayed urination, disconnected urination, abdominal urination, uremic weakness, residual urine, urinary retention, or mixed symptoms thereof. .
본 발명의 구체적인 실시예에 따르면, 육계 추출물 및 황기 추출물을 포함하는 조성물은 전립선 비대증에서, 전립선 조직이 커지는 것을 억제한다. 또한, 본 발명의 다른 구체적인 실시예에 따르면, 육계 추출물 및 황기 추출물을 포함하는 조성물은 전립선 비대증에서 5α-리덕타아제의 발현을 억제한다. 따라서 본 발명의 약제학적 조성물은 전립선 비대증의 예방 또는 치료용으로 효과적으로 사용될 수 있다.According to a specific embodiment of the present invention, a composition comprising a broiler extract and astragalus extract inhibits prostate tissue from growing in prostatic hyperplasia. In addition, according to another specific embodiment of the present invention, a composition comprising a broiler extract and astragalus extract inhibits the expression of 5α-reductase in prostatic hyperplasia. Therefore, the pharmaceutical composition of the present invention can be effectively used for the prevention or treatment of prostatic hyperplasia.
본 발명에서, "유효성분"은 단독으로 목적하는 활성을 나타내거나, 그 자체는 활성이 없는 담체와 함께 활성을 나타낼 수 있는 성분을 의미한다.In the present invention, "active ingredient" refers to a component that can exhibit the desired activity alone, or itself can exhibit activity with an inactive carrier.
본 발명에서, "예방"은 본 발명의 약제학적 조성물의 투여에 의해 전립선 비대증과 연관된 하나 이상의 증상의 발생 또는 발병이 억제되거나 지연되는 모든 행위를 의미하며, 반드시 전립선 비대증의 완전한 발병 억제를 의미하는 것은 아니다. In the present invention, "prophylaxis" refers to any action that inhibits or delays the onset or development of one or more symptoms associated with prostatic hyperplasia by administration of the pharmaceutical composition of the present invention, and necessarily means the complete inhibition of prostate hyperplasia. It is not.
본 발명에서, "치료"는 본 발명의 약제학적 조성물의 투여에 의해 전립선 비대증과 연관된 하나 이상의 증상을 나타내고 있거나, 이전에 나타냈던 개체의 증상이 억제되거나, 감소되거나 또는 호전되는 모든 행위를 의미한다. 상기 개체는 인간을 포함하는 포유류일 수 있으며, 바람직하게는 인간이다.In the present invention, "treatment" refers to any action that exhibits one or more symptoms associated with prostate hyperplasia by the administration of a pharmaceutical composition of the present invention, or that the symptoms of an individual previously exhibited are suppressed, reduced or improved. . The subject may be a mammal, including a human being, and is preferably a human being.
본 발명에서, "투여"는 어떠한 적절한 방법으로 개체에 본 발명의 약제학적 조성물을 도입하는 것을 의미한다. 투여 경로는 목적 조직에 도달할 수 있는 한 어떠한 일반적인 경로를 통하여 경구 또는 비경구 투여될 수 있다. 또한, 본 발명의 약제학적 조성물이 표적 세포로 이동할 수 있도록 하는 임의의 장치에 의해 투여될 수 있다.In the present invention, "administration" means introducing the pharmaceutical composition of the present invention to an individual in any suitable way. The route of administration can be administered orally or parenterally through any general route as long as the target tissue can be reached. In addition, the pharmaceutical composition of the present invention can be administered by any device that allows it to migrate to target cells.
본 발명의 약제학적 조성물은 본 발명의 효과를 해치지 않는 범위에서 약제학적으로 허용되는 담체를 추가로 포함할 수 있다. 본 발명에서 사용될 수 있는 약제학적으로 허용되는 담체의 종류는 특별히 제한되지 아니하며, 이 기술 분야에서 통상적으로 사용되는 담체라면 어느 것이든 사용할 수 있다. 상기 담체는 예를 들어, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사 용액, 락토오스, 덱스트로오스, 수크로오스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 말토 덱스트린, 글리세롤, 에탄올 등을 들 수 있으나, 이에 한정되는 것은 아니다. 상기 담체는 단독으로 사용되거나 2 종 이상을 혼합하여 사용될 수 있다.The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier in a range that does not impair the effects of the present invention. The type of the pharmaceutically acceptable carrier that can be used in the present invention is not particularly limited, and any carrier commonly used in the art can be used. Examples of the carrier include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, maltodextrin, glycerol, ethanol, etc. , But is not limited thereto. The carrier may be used alone or in combination of two or more.
본 발명의 약제학적 조성물은 본 발명의 효과를 해치지 않는 범위에서 약제학적으로 허용되는 첨가제를 추가로 포함할 수 있다. 본 발명에서 사용될 수 있는 약제학적으로 허용되는 첨가제의 종류는 특별히 제한되지 아니하며 이 기술 분야에서 통상적으로 사용되는 첨가제라면 어느 것이든 사용할 수 있다. 상기 첨가제는 예를 들어, 충전제, 결합제, 붕해제, 윤활제, 현탁화제, 용제, 산화방지제, pH 조절제, 습윤제, 감미제 및 보존제를 들 수 있으나, 이에 한정되지는 것은 아니다. 상기 첨가제는 단독으로 사용되거나 2 종 이상을 혼합하여 사용될 수 있다.The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable additive in a range that does not impair the effects of the present invention. The types of pharmaceutically acceptable additives that can be used in the present invention are not particularly limited, and any additives commonly used in the art can be used. Examples of the additives include, but are not limited to, fillers, binders, disintegrants, lubricants, suspending agents, solvents, antioxidants, pH adjusting agents, wetting agents, sweeteners and preservatives. The additives may be used alone or in combination of two or more.
본 발명의 약제학적 조성물은 경구 투여 또는 비경구 투여를 위한 적합하고 다양한 제형이 될 수 있다. 본 발명에서, 경구 투여용 제형은 예를 들어, 정제, 환제, 분말, 산제, 과립, 펠렛, 캡슐, 트로키(troches), 로젠지(lozenge), 현탁액, 에멀젼, 시럽 및 엘릭시르제 등을 들 수 있으나, 이에 한정되는 것은 아니다. 본 발명에서, 비경구 투여용 제형은 예를 들어, 주사제, 좌제, 호흡기 흡입제, 에어로졸제, 연고, 도포용 분말, 오일, 크림, 겔 및 샴푸 등을 들 수 있으나, 이에 한정되는 것은 아니다.The pharmaceutical composition of the present invention may be suitable and various formulations for oral administration or parenteral administration. In the present invention, oral dosage forms include, for example, tablets, pills, powders, powders, granules, pellets, capsules, troches, lozenges, suspensions, emulsions, syrups and elixirs. However, it is not limited thereto. In the present invention, the formulation for parenteral administration may include, for example, injections, suppositories, respiratory inhalers, aerosols, ointments, powders for application, oils, creams, gels, and shampoos, but is not limited thereto.
본 발명의 약제학적 조성물은 목적에 따라 경구 투여하거나 비경구 투여할 수 있다. 본 발명에서, 비경구 투여는 예를 들어, 복강 투여, 직장 투여, 피하 투여, 정맥 투여, 근육 투여, 흉부 투여 및 경피 투여를 들 수 있고, 조성물을 질환 부위에 도포하거나 분무, 흡입하는 것도 들 수 있으나. 이에 한정되는 것은 아니다. 본 발명의 구체적인 구현예에서, 본 발명의 약제학적 조성물은 경구 투여될 수 있다.The pharmaceutical composition of the present invention may be administered orally or parenterally depending on the purpose. In the present invention, parenteral administration includes, for example, intraperitoneal administration, rectal administration, subcutaneous administration, intravenous administration, intramuscular administration, thoracic administration, and transdermal administration, and the composition is applied to a diseased site, sprayed, or inhaled. You can. It is not limited to this. In a specific embodiment of the invention, the pharmaceutical composition of the invention can be administered orally.
본 발명의 약학적 조성물은 약학적으로 유효한 양으로 투여한다. 본 발명에서, "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효한 양의 수준은 환자의 상태, 체중, 성별, 연령, 건강상태, 질병의 정도, 약물에 대한 민감도, 투여 시간, 투여 경로, 배출 비율, 치료 기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 약제학적 조성물의 투여량은 통상의 기술자에 의해 적절하게 선택될 수 있다. 본 발명의 약제학적 조성물의 투여량은 육계 추출물 및 황기 추출물의 함량을 기준으로 1일 0.1 mg/kg 내지 1,000 mg/kg 일 수 있고, 보다 바람직하게는 1 mg/kg 내지 100 mg/kg 일 수 있으나, 이에 제한되는 것은 아니다. 또한, 상기 투여량의 본 발명의 범위를 한정하는 것은 아니다.The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, "a pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective amount level is the patient's condition, weight, sex, age, and health It can be determined according to the condition, the degree of disease, the sensitivity to the drug, the time of administration, the route of administration, the rate of excretion, the duration of treatment, factors including drugs used concurrently, and other factors well known in the medical field. The dosage of the pharmaceutical composition of the present invention can be appropriately selected by a person skilled in the art. The dosage of the pharmaceutical composition of the present invention may be 0.1 mg/kg to 1,000 mg/kg per day, more preferably 1 mg/kg to 100 mg/kg per day based on the content of broiler extract and astragalus extract. However, it is not limited thereto. In addition, the scope of the present invention is not limited to the above dosage.
본 발명의 약제학적 조성물의 투여는 하루에 한 번 투여할 수도 있고, 수회 나누어 투여할 수도 있으며, 수일에 한 번 투여할 수도 있다. The pharmaceutical composition of the present invention may be administered once a day, may be administered several times, or may be administered once every several days.
본 발명의 약제학적 조성물은 전립선 비대증의 예방 및 치료를 위하여 단독으로, 또는 다른 예방 또는 치료제와 병용하여 투여될 수 있고, 다른 예방 또는 치료제와 동시에 또는 순차적으로 투여될 수 있다. 또한, 본 발명의 약제학적 조성물은 수술, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용될 수 있다.The pharmaceutical composition of the present invention may be administered alone or in combination with other prophylactic or therapeutic agents for the prevention and treatment of prostatic hyperplasia, and may be administered simultaneously or sequentially with other prophylactic or therapeutic agents. In addition, the pharmaceutical composition of the present invention can be used in combination with methods using surgery, hormone therapy, chemotherapy, and biological response modifiers.
본 발명은 육계 추출물 및 황기 추출물을 유효성분으로 포함하는 전립선 비대증의 예방 또는 개선용 식품 조성물을 제공한다.The present invention provides a food composition for preventing or improving prostatic hyperplasia comprising broiler extract and astragalus extract as active ingredients.
본 발명의 식품 조성물에서, 육계, 황기, 추출물, 유효성분 및 전립선 비대증은 앞서 본 발명의 약제학적 조성물에 대해 상세하게 기재한 바와 동일하다.In the food composition of the present invention, broiler, astragalus, extract, active ingredient and prostatic hyperplasia are the same as described in detail for the pharmaceutical composition of the present invention.
본 발명의 구체적인 실시예에 따르면, 육계 추출물 및 황기 추출물을 포함하는 조성물은 전립선 비대증에서, 전립선 조직이 커지는 것을 억제한다. 또한, 본 발명의 다른 구체적인 실시예에 따르면, 육계 추출물 및 황기 추출물을 포함하는 조성물은 전립선 비대증에서 5α-리덕타아제의 발현을 억제한다. 따라서 본 발명의 식품 조성물은 전립선 비대증의 예방 또는 개선용으로 효과적으로 사용될 수 있다.According to a specific embodiment of the present invention, a composition comprising a broiler extract and astragalus extract inhibits prostate tissue from growing in prostatic hyperplasia. In addition, according to another specific embodiment of the present invention, a composition comprising a broiler extract and astragalus extract inhibits the expression of 5α-reductase in prostatic hyperplasia. Therefore, the food composition of the present invention can be effectively used for preventing or improving prostatic hyperplasia.
본 발명에서, "예방"은 본 발명의 식품 조성물의 섭취에 의해 전립선 비대증과 연관된 하나 이상의 증상의 발생 또는 발병이 억제되거나 지연되는 모든 행위를 의미하며, 반드시 전립선 비대증의 완전한 발병 억제를 의미하는 것은 아니다. In the present invention, "prophylaxis" means any action that suppresses or delays the development or development of one or more symptoms associated with prostatic hyperplasia by ingestion of the food composition of the present invention, and necessarily means the complete inhibition of prostate hyperplasia. no.
본 발명에서, "개선"은 본 발명의 식품 조성물의 섭취에 의해 전립선 비대증과 연관된 하나 이상의 증상의 정도가 감소되거나 호전되거나 진행이 지연되는 모든 행위를 의미한다.In the present invention, "improvement" means any action in which the intake of the food composition of the present invention reduces, improves or delays progression of one or more symptoms associated with prostatic hyperplasia.
본 발명의 식품 조성물은 육계 추출물 및 황기 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. The food composition of the present invention may be added as a broiler extract and astragalus extract as it is or may be used together with other food or food ingredients, and may be suitably used according to conventional methods.
본 발명의 식품 조성물은 육계 추출물 및 황기 추출물을 유효성분으로 포함하며, 유효성분의 함량은 사용 목적에 따라 적합하게 결정될 수 있다. 일반적으로, 육계 추출물 및 황기 추출물은 식품 조성물의 총중량에 대하여 0.0001 내지 100 중량%로 첨가될 수 있다.Food composition of the present invention includes a broiler extract and astragalus extract as an active ingredient, the content of the active ingredient may be appropriately determined according to the purpose of use. In general, broiler extract and astragalus extract may be added at 0.0001 to 100% by weight based on the total weight of the food composition.
본 발명에서, 식품 조성물의 형태에는 특별한 제한이 없으며, 통상적인 의미에서의 식품을 모두 포함한다. 본 발명이 적용될 수 있는 식품으로는, 예를 들어, 음료, 드링크제, 건강기능식품 등이 있다.In the present invention, the form of the food composition is not particularly limited, and includes all foods in the ordinary sense. Foods to which the present invention can be applied include, for example, beverages, drinks, and health functional foods.
본 발명에서, "건강기능식품"은 인체에 유용한 기능성을 가진 원료나 성분을 사용하여, 영양 공급 외에도 생체조절기능이 효율적으로 나타나도록 제조 및 가공한 식품을 의미한다. 상기 건강기능식품은 경우에 따라, 기능성식품, 건강식품 또는 건강보조식품 등의 용어와 호용된다. 또한, 본 발명에서, "기능"이란 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적인 작용으로 보건 용도에 유용한 효과를 의미할 수 있다.In the present invention, "health functional food" means a food prepared and processed so that a bio-control function is efficiently displayed in addition to nutritional supply, by using a raw material or a component having useful functionality for the human body. The health functional food is used interchangeably with terms such as a functional food, a health food, or a health supplement, as the case may be. In addition, in the present invention, "function" may mean an effect useful for health use by controlling nutrients or physiological action on the structure and function of the human body.
본 발명의 식품 조성물은 통상적으로 식품의 냄새, 맛 또는 시각 등을 향상시킬 수 있는 식품 첨가제를 추가로 더 포함할 수 있다. 상기 식품 첨가제는 예를 들어, 풍미제, 증진제, 탄산화제 방부제(소르빈산 칼륨, 벤조산나트륨, 살리실산, 디히드로초산나트륨 등), 살균제(표백분과 고도 표백분, 차아염소산나트륨 등), 산화방지제(부틸히드록시아니졸, 부틸히드록시톨루엔등), 착색제(타르색소 등), 발색제(아질산 나트륨, 아초산 나트륨 등), 표백제(아황산나트륨), 조미료(MSG 글루타민산나트륨 등), 감미료(둘신, 사이클레메이트, 사카린, 나트륨 등), 향료(바닐린, 락톤류 등), 팽창제(명반, D-주석산수소칼륨 등), 강화제, 유화제, 증점제(호료), 피막제, 검기초제, 거품억제제, 용제 및 개량제를 들 수 있으나, 이에 한정되는 것은 아니다. 상기 첨가물은 식품의 종류에 따라 선별되고 적절한 양으로 사용될 수 있다.The food composition of the present invention may further include a food additive that can generally improve the odor, taste, or vision of the food. The food additives include, for example, flavoring agents, enhancers, preservatives for carbonation agents (potassium sorbate, sodium benzoate, salicylic acid, sodium dihydroacetate, etc.), fungicides (bleaching and highly bleaching, sodium hypochlorite, etc.), antioxidants (butyl hydride) Roxyanisol, butylhydroxytoluene, etc.), colorants (such as tar color), colorants (sodium nitrite, sodium nitrite, etc.), bleach (sodium sulfite), seasonings (such as MSG sodium glutamate), sweeteners (dulcin, cyclate) , Saccharin, sodium, etc.), fragrances (vanillin, lactones, etc.), swelling agents (alum, D-potassium hydrogen sulphate, etc.), strengthening agents, emulsifiers, thickeners (foams), coating agents, gum starting agents, foam inhibitors, solvents and improvers However, it is not limited thereto. The additive may be selected according to the type of food and used in an appropriate amount.
본 발명의 식품 조성물은 식품의 기능성을 향상시킬 수 있는 추가의 성분을 더 포함할 수 있다. 예들 들어, 비타민(vitamin), 니아신(niacin), 비오틴(biotin), 폴레이트(folate), 판토텐산(panthotenic acid) 등을 포함할 수 있다. 또한, 아연(Zn), 철(Fe), 칼슘(Ca), 크롬(Cr), 마그네슘(Mg), 망간(Mn), 구리(Cu) 등의 미네랄을 포함할 수 있다. 또한, 라이신, 트립토판, 시스테인, 발린 등의 아미노산을 포함할 수 있다. The food composition of the present invention may further include additional ingredients that can improve the functionality of the food. For example, vitamins (vitamin), niacin (niacin), biotin (biotin), folate (folate), may include pantotenic acid (panthotenic acid). In addition, minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), and copper (Cu) may be included. In addition, amino acids such as lysine, tryptophan, cysteine, and valine may be included.
본 발명의 식품 조성물은 식품 첨가물로 사용할 수 있으며, 이를 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다.The food composition of the present invention can be used as a food additive, it can be added as it is or used with other food or food ingredients, it can be suitably used according to a conventional method.
본 발명의 식품 조성물이 음료 또는 드링크제인 경우, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 향미제는 예를 들어, 사카린, 아스파르탐 등을 들 수 있다. 상기 천연 탄수화물은 예를 들어, 포도당, 과당 등의 모노사카라이드; 말토스, 수크로스 등의 디사카라이드; 및 덱스트린, 시클로덱스트린 등의 폴리사카라이드와 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트릴톨 등의 당알콜을 들 수 있다. 그 밖에 본 발명의 식품 조성물은 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다.When the food composition of the present invention is a beverage or drink, various flavors or natural carbohydrates and the like may be added as additional components, as in a conventional beverage. Examples of the flavoring agent include saccharin and aspartame. The natural carbohydrates include, for example, monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; And conventional sugars such as polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. In addition, the food composition of the present invention may contain flesh for the preparation of natural fruit juice, fruit juice beverage and vegetable beverage. These ingredients may be used independently or in combination.
본 발명의 식품 조성물은 여러 가지 영양제, 비타민, 전해질, 합성 또는 천연 풍미제, 착색제, 증진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산화제 등을 함유할 수 있다.The food composition of the present invention includes various nutrients, vitamins, electrolytes, synthetic or natural flavors, colorants, enhancers, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, Glycerin, alcohol, carbonic acid, and the like.
육계 추출물 및 황기 추출물을 포함하는 조성물은 전립선 비대증에서 전립선 조직이 커지는 것을 억제한다. 또한, 육계 추출물 및 황기 추출물을 포함하는 조성물은 전립선 비대증에서 5α-리덕타아제의 발현을 억제한다. 따라서 육계 추출물 및 황기 추출물을 유효성분으로 포함하는 본 발명의 약제학적 조성물 및 식품 조성물은 전립선 비대증의 예방, 치료 또는 개선용으로 효과적으로 사용될 수 있다.The composition comprising a broiler extract and astragalus extract inhibits the growth of prostate tissue in prostatic hyperplasia. In addition, the composition comprising a broiler extract and astragalus extract inhibits the expression of 5α-reductase in prostatic hyperplasia. Therefore, the pharmaceutical composition and food composition of the present invention comprising a broiler extract and astragalus extract as an active ingredient can be effectively used for the prevention, treatment or improvement of prostatic hyperplasia.
도 1은 실시예 1에서 정상대조군(NC), 음성대조군(BPH) 및 실험군(Sample group)의 전립선 조직을 관찰한 사진이다.
도 2는 실시예 1에서 정상대조군(NC), 음성대조군(BPH) 및 실험군(Sample group)의 체중(body weight)을 나타낸 그래프이다.
도 3은 실시예 1에서 정상대조군(NC), 음성대조군(BPH) 및 실험군(Sample group)의 전립선 조직 무게(prostate tissue weight)를 나타낸 그래프이다.
도 4는 실시예 1에서 정상대조군(NC), 음성대조군(BPH) 및 실험군(Sample group)의 Prostate index를 나타낸 그래프이다.
도 5는 실시예 2에서 정상대조군(NC), 음성대조군(BPH) 및 실험군(Sample group)의 조직을 염색하여 광학 현미경으로 관찰한 것을 나타낸 것이다.
도 6은 실시예 3에서 정상대조군(NC), 음성대조군(BPH) 및 실험군(Sample group)의 5α-리덕타아제 발현 정도를 웨스턴 블롯으로 확인한 결과를 나타낸 사진 및 그래프이다.1 is a photograph of the prostate tissue of the normal control group (NC), the negative control group (BPH) and the experimental group (Sample group) in Example 1.
2 is a graph showing the body weight of the normal control group (NC), the negative control group (BPH), and the experimental group (Sample group) in Example 1.
3 is a graph showing the prostate tissue weight of the normal control group (NC), the negative control group (BPH), and the experimental group (Sample group) in Example 1.
4 is a graph showing the Prostate index of the normal control group (NC), the negative control group (BPH), and the experimental group (Sample group) in Example 1.
FIG. 5 shows that the tissues of the normal control group (NC), the negative control group (BPH) and the experimental group (Sample group) in Example 2 were stained and observed with an optical microscope.
FIG. 6 is a photograph and graph showing the results of confirming the 5α-reductase expression level of the normal control group (NC), the negative control group (BPH), and the experimental group in Example 3 by Western blot.
이하에서, 본 발명을 구체적인 제조예 및 실시예를 통하여 보다 상세히 설명한다. 그러나 하기 실시예는 본 발명의 이해를 돕기 위하여 제공되는 것일 뿐, 실시예에 의하여 본 발명의 범위가 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through specific production examples and examples. However, the following examples are provided only to help understanding of the present invention, and the scope of the present invention is not limited by the examples.
<제조예><Production Example>
제조예 1: 육계 추출물의 제조Preparation Example 1: Preparation of broiler extract
육계(500 g)에 3차 증류수(3.75 L)를 가하여 100 ℃에서 2시간 열수 추출한 후 여과하였다. 여과액을 55 ± 2 ℃에서 회전 감압농축기(rotary vacuum evaporator, EYELA, Tokyo, Japan)로 감압 농축 후, 동결 건조하여 20.1 g 파우더 상태의 육계 열수 추출물(수율: 4%)을 수득하였다.Tertiary distilled water (3.75 L) was added to broiler (500 g), followed by extraction with hot water at 100° C. for 2 hours, followed by filtration. The filtrate was concentrated under reduced pressure with a rotary vacuum evaporator (EYELA, Tokyo, Japan) at 55±2° C., and then freeze-dried to obtain a 20.1 g powder broiler hot water extract (yield: 4%).
제조예 2: 황기 추출물의 제조Preparation Example 2: Preparation of astragalus extract
황기는 정도 생약국(Seoul, Korea)에서 건조된 뿌리 형태로 구입한 후 경희대학교 한의과대학 융합한의과학교실에서 형태학적 및 화학적으로 동정하여 사용하였다. 황기(150 g)에 증류수(1.5 L)을 가하여 100 ℃에서 2시간 열수추출 한 후 여과하였다. 여과액을 55 ± 2 ℃에서 회전 감압농축기(rotary vacuum evaporator, EYELA, Tokyo, Japan)로 감압 농축 후, 동결 건조하여 24.3 g 파우더 상태의 황기 열수 추출물(수율: 16.2%)을 수득하였다.Hwanggi was purchased in the form of dried roots from the Soyak, Korea, and was used for morphological and chemical identification in the Department of Convergence Medicine, College of Oriental Medicine, Kyunghee University. Distilled water (1.5 L) was added to sulfuric acid (150 g), followed by extraction with hot water at 100° C. for 2 hours, followed by filtration. The filtrate was concentrated under reduced pressure with a rotary vacuum evaporator (EYELA, Tokyo, Japan) at 55±2° C., and then freeze-dried to obtain a 24.3 g powdered astragalus hot water extract (yield: 16.2%).
제조예 3: 육계 및 황기 복합 추출물의 제조Preparation Example 3: Preparation of broiler and astragalus complex extract
제조예 1에서 수득한 육계 추출물 및 제조예 2에서 수득한 황기 추출물을 1 : 4 의 중량 비율로 혼합하여 육계 및 황기 복합 추출물을 수득하였다.The broiler extract obtained in Preparation Example 1 and the astragalus extract obtained in Preparation Example 2 were mixed at a weight ratio of 1: 4 to obtain a broiler and astragalus complex extract.
<실시예> 육계 및 황기 복합 추출물을 포함하는 조성물의 전립선 비대증 예방, 치료 및 개선 효과 확인<Example> Prophylactic hyperplasia prevention, treatment, and improvement effect confirmation of a composition containing a broiler and astragalus complex extract
실험 동물Experimental animals
실시예 1 내지 3에서 실험동물은 체중 20 g 내외의 암컷 7주령의 C57BL/6J 정상 생쥐를 이용하였다. 모든 생쥐는 대한바이오링크(충북, 음성)로부터 구매하여 일주일 동안의 적응기를 통해 본 실험에 사용되었다. 전 실험 기간 동안 모든 생쥐들은 표준화된 고형사료와 물을 공급받았으며, 사육실의 온도는 23 ± 2 ℃, 습도 50 ± 10%, 광주기와 암주기(light-dark cycle)는 12시간-12시간으로 유지되었다. In Examples 1 to 3, the experimental animals used C57BL/6J normal mice of 7 weeks of age and females with a body weight of about 20 g. All mice were purchased from Daehan Biolink (Chungbuk, Eumseong) and used in this experiment through an adaptive period of one week. During the entire experimental period, all mice were supplied with standardized solid feed and water, and the temperature in the breeding room was 23 ± 2 ℃, humidity 50 ± 10%, and photoperiod and dark-dark cycles were maintained for 12 hours-12 hours. Became.
실험 모델 유발 및 약물 처리Experimental model triggering and drug treatment
각 군의 생쥐(n = 6)는 정상대조군(NC, normal control group), 전립선 비대증이 유도된 음성대조군(BPH, negative control group), 전립선 비대증이 유도된 생쥐에 제조예 3의 복합 추출물을 처리한 실험군(sample group)으로 나뉘어졌다. 전립선 비대증 유발을 위해 14일간 에탄올과 옥수수 오일에 희석한 테스토스테론 프로피온산을 5 mg/kg/day의 농도로 피하주사 하였다. 정상대조군과 음성대조군에는 비히클(증류수)을 처리하였으며, 제조예 3의 복합 추출물은 10 mg/kg의 양으로 처리하였고, 증류수에 녹여 100 μL씩 피하주사 하였다. 매일 1회씩 총 14일간 반복하였으며, 15일 째 되는 날 실험 목적에 따라 생쥐를 희생하였다. 분석을 위하여 병변 부위의 전립선 조직을 적출하였다. 적출된 전립선 조직을 이하의 실시예 1 내지 3에 사용하였다.In each group of mice (n = 6), a normal control group (NC), a prostate hyperplasia-induced negative control group (BPH, negative control group), and a prostate hyperplasia-induced mouse treated with the complex extract of Preparation Example 3 It was divided into one sample group. To induce prostatic hyperplasia, testosterone propionic acid diluted in ethanol and corn oil for 14 days was injected subcutaneously at a concentration of 5 mg/kg/day. The normal control group and the negative control group were treated with vehicle (distilled water), and the complex extract of Preparation Example 3 was treated with an amount of 10 mg/kg, dissolved in distilled water and injected subcutaneously at 100 μL. It was repeated once a day for a total of 14 days, and mice were sacrificed according to the purpose of the experiment on the 15th day. For analysis, prostate tissue at the lesion site was isolated. The extracted prostate tissue was used in Examples 1 to 3 below.
통계처리Statistics processing
실시예 1 내지 3에서 실험 결과는 평균 ± 표준오차(mean ± S.E.M) 값으로 표시하였으며, 집단 간 평균치 차이는 각 실험 결과를 통하여 ANOVA (analysis of variance)를 구한 후 던칸 다중 범위 검정(Duncan's multiple range test)을 이용하여 p < 0.05 수준에서 검증하였다.In Examples 1 to 3, the experimental results were expressed as mean ± standard error (mean ± SEM) values, and the mean difference between groups was calculated through ANOVA (analysis of variance) through each experimental result, followed by Duncan's multiple range test. test) at p <0.05 level.
실시예 1: 전립선 조직 관찰Example 1: Prostate tissue observation
육계 및 황기 복합 추출물의 전립선 비대증 개선 효과를 관찰하기 위해 희생시킨 생쥐를 개복, 전립선 조직을 적출하여 조직의 육안적 크기를 정상대조군 및 음성대조군과 비교 관찰하였으며, 그 결과를 도 1에 나타내었다. 또한, 그 후 각 군의 마우스의 체중, 전립선 조직의 무게를 측정하고, 전립선 조직 무게(mg)를 마우스의 체중(g)으로 나누어 Prostae index를 계산하였으며, 그 결과를 도 2 내지 4에 나타내었다.In order to observe the effect of improving the prostate hyperplasia of broiler and astragalus complex extracts, the mice sacrificed were opened, the prostate tissue was extracted, and the gross size of the tissues was compared with the normal and negative controls, and the results are shown in FIG. 1. Further, after that, the weight of each group of mice and the weight of the prostate tissue were measured, and the Prostae index was calculated by dividing the prostate tissue weight (mg) by the weight of the mouse (g), and the results are shown in FIGS. 2 to 4. .
도 1에 나타낸 바와 같이, 육계 및 황기 복합 추출물을 처리한 군에서 음성대조군 대비 전립선 조직의 비대 정도가 적은 것을 육안으로도 쉽게 확인할 수 있다.As shown in Figure 1, it can be easily confirmed even with the naked eye that the degree of hypertrophy of the prostate tissue is less than that of the negative control group in the group treated with the broiler and astragalus complex extracts.
또한, 도 2 내지 4에 나타낸 바와 같이 전립선 조직의 무게는 음성대조군이 가장 무거웠고, 육계 및 황기 복합 추출물을 투여한 실험군의 경우 음성대조군 대비 전립선 조직 무게가 더 적었으며, Prostate index 계산 결과로도 육계 및 황기 복합 추출물을 투여한 실험군의 수치가 우수하였다. 따라서, 본 발명의 육계 추출물 및 황기 추출물을 유효성분으로 포함하는 조성물은 전립선 비대증의 예방, 치료 및 개선용으로 효과적으로 사용될 수 있다.In addition, as shown in FIGS. 2 to 4, the weight of the prostate tissue was the heaviest in the negative control group, and in the case of the experimental group in which the broiler and astragalus complex extract was administered, the weight of the prostate tissue was less than that in the negative control group, and also as a result of calculating the Prostate index. The experimental group administered with the broiler and astragalus complex extracts had excellent values. Therefore, the composition comprising the broiler extract and the astragalus extract of the present invention as an active ingredient can be effectively used for the prevention, treatment and improvement of prostatic hyperplasia.
실시예 2: 조직학적 평가Example 2: Histological evaluation
적출한 전립선 조직을 24시간 동안 4% 포르말린에 고정한 후, 조직의 탈수를 위해 순서대로 저농도의 70% 에탄올부터 80% 에탄올, 90% 에탄올, 95% 에탄올 및 고농도 100% 알코올까지 탈수하고, 자일렌에 투명과정을 거친 다음 파라핀 블록을 제작하였다. 제작된 블록은 4 μm 두께로 박절하여 탈파라핀 및 100% 에탄올에서 70% 에탄올을 거쳐 함수시켰다. 증류수에 수세시킨 조직 슬라이드를 헤마토실린(hematoxylin) & 에오신(eosin) (H&E)으로 각각 염색하여 퍼마운트(permount)로 봉입하였다. 염색된 조직은 광학현미경(Leica Microsystems Inc., IL, USA)에서 × 200 배율로 관찰하였으며, 그 결과를 도 5에 나타내었다.The extracted prostate tissue is fixed in 4% formalin for 24 hours, and then dehydrated from low concentration of 70% ethanol to 80% ethanol, 90% ethanol, 95% ethanol and high concentration 100% alcohol in order for dehydration of the tissue. After going through a transparent process, a paraffin block was produced. The produced block was sliced to a thickness of 4 μm, and then dehydrated through deparaffin and 100% ethanol to 70% ethanol. Tissue slides washed with distilled water were stained with hematoxylin & eosin (H&E), respectively, and sealed with a permount. The dyed tissue was observed under an optical microscope (Leica Microsystems Inc., IL, USA) at a magnification of 200, and the results are shown in FIG. 5.
도 5에 나타낸 바와 같이, 음성대조군에서는 테스토스테론 프로피온산 주입에 의해 전립선에서 상피조직의 두께 비후화 및 내강면적의 감소가 관찰된 반면, 육계 및 황기 복합추출물을 투여한 군에서는 비후화된 전립선조직의 상피두께가 감소하고 내강면적이 넓어진 것으로 보아 전립선 비대증이 개선된 것을 확인할 수 있다. 따라서, 본 발명의 육계 추출물 및 황기 추출물을 유효성분으로 포함하는 조성물은 전립선 비대증의 예방, 치료 및 개선용으로 효과적으로 사용될 수 있다.As shown in FIG. 5, in the negative control group, thickening of the epithelial tissue and reduction in lumen area were observed in the prostate by injection of testosterone propionic acid, whereas in the group administered with the broiler and astragalus complex extracts, the epithelial of the thickened prostate tissue It can be seen that the enlarged prostate hyperplasia was improved by reducing the thickness and widening the lumen area. Therefore, the composition comprising the broiler extract and the astragalus extract of the present invention as an active ingredient can be effectively used for the prevention, treatment and improvement of prostatic hyperplasia.
실시예 3: 5α-리덕타아제 억제 확인 (웨스턴 블롯)Example 3: Confirmation of 5α-reductase inhibition (Western Blot)
적출된 전립선 조직의 단백질을 추출하기 위하여 프로테아제 억제제 칵테일(protease inhibitors cocktail)이 포함된 단백질 추출 버퍼(protein extraction buffer) (50 mM Tris-HCl, 150 mM NaCl, 1% 트리톤 X-100, 1% 디옥시콜산 나트륨, 0.1% 도데실 황산 나트륨(SDS), 2 mM 에틸렌디아민테트라 아세트산(EDTA))를 넣어 분쇄하였다. 얻어진 단백질은 브래드포드(bradford) 법을 사용하여 정량하였다. 정량된 단백질 30 μg을 SDS 12% 폴리아크릴아미드 젤(polyacrylamide gel)에 전기영동하여 분리한 후 폴리비닐리덴 디플루오라이드(PVDF) 멤브레인으로 이동시켰다. 1차 항체를 반응시킨 후, 호스래디시 퍼옥시다아제(HRP) goat anti-rabbit을 처리하여 2차 반응을 유도시켰다. 발현된 단백질 밴드는 강화된 화학발광 분석 키트(enhanced chemiluminescence assay kit)를 이용하여 LAS 이미지 게이지(LAS Image Gauge) 프로그램에서 측정하였으며, 그 결과를 도 6에 나타내었다.Protein extraction buffer containing protease inhibitors cocktail (50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 1% D) to extract the extracted prostate tissue protein Sodium oxycholate, 0.1% sodium dodecyl sulfate (SDS) and 2 mM ethylenediaminetetraacetic acid (EDTA) were added and pulverized. The obtained protein was quantified using the Bradford method. 30 μg of the quantified protein was separated by electrophoresis on SDS 12% polyacrylamide gel, and then transferred to a polyvinylidene difluoride (PVDF) membrane. After reacting the primary antibody, a secondary reaction was induced by treating horseradish peroxidase (HRP) goat anti-rabbit. The expressed protein band was measured in a LAS Image Gauge program using an enhanced chemiluminescence assay kit, and the results are shown in FIG. 6.
도 6에 나타낸 바와 같이, 음성 대조군의 경우 5α-리덕타아제의 발현이 크게 증가하였으나, 육계 및 황기 복합 추출물을 투여한 실험군의 경우 5α-리덕타아제의 발현 증가가 크게 완화됨을 확인할 수 있다. 따라서, 본 발명의 육계 추출물 및 황기 추출물을 유효성분으로 포함하는 조성물은 전립선 비대증의 예방, 치료 및 개선용으로 효과적으로 사용될 수 있다.As shown in FIG. 6, the expression of 5α-reductase was significantly increased in the case of the negative control group, but the expression increase of 5α-reductase was significantly reduced in the experimental group administered with the broiler and astragalus complex extracts. Therefore, the composition comprising the broiler extract and the astragalus extract of the present invention as an active ingredient can be effectively used for the prevention, treatment and improvement of prostatic hyperplasia.
이상의 설명으로부터, 본 발명이 속하는 기술분야의 통상의 기술자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로서 이해되어야 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, those skilled in the art to which the present invention pertains will appreciate that the present invention may be implemented in other specific forms without changing its technical spirit or essential characteristics. In this regard, the examples described above should be understood as illustrative in all respects and not restrictive. The scope of the present invention should be construed as including all changes or modifications derived from the meaning and scope of the following claims rather than the detailed description and equivalent concepts thereof.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180006423A KR102129412B1 (en) | 2018-01-18 | 2018-01-18 | Composition for preventing, improving or treating benign prostatic hyperplasia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180006423A KR102129412B1 (en) | 2018-01-18 | 2018-01-18 | Composition for preventing, improving or treating benign prostatic hyperplasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190088201A KR20190088201A (en) | 2019-07-26 |
| KR102129412B1 true KR102129412B1 (en) | 2020-07-02 |
Family
ID=67469676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180006423A KR102129412B1 (en) | 2018-01-18 | 2018-01-18 | Composition for preventing, improving or treating benign prostatic hyperplasia |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102129412B1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006176508A (en) | 2004-12-21 | 2006-07-06 | Golden Biotechnology Corp | Composition for inhibiting growth of prostate cancer cell and method for formulation the same |
| CN102240344B (en) | 2011-07-04 | 2013-01-09 | 辅仁药业集团有限公司 | Radix astragali capsule for treating cerebral ischemia |
| JP2017039689A (en) * | 2015-08-18 | 2017-02-23 | ゴールデン バイオテクノロジー コーポレーション | Add-on treatment of benign prostatic hyperplasia |
| CN107137571A (en) | 2017-04-05 | 2017-09-08 | 吴忠市仁爱医院有限公司 | A kind of Chinese medicine composition for treating prostatitis and hypertrophy of the prostate |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120020579A (en) * | 2010-08-30 | 2012-03-08 | 주식회사한국전통의학연구소 | Composition comprising cinnamon for treatment of prostate cancer |
| KR101814033B1 (en) * | 2016-01-08 | 2018-01-02 | 정선아라리한과농원 영농조합법인 | Grain syrup comprising astragalus membranaceus and manufacturing method thereof |
-
2018
- 2018-01-18 KR KR1020180006423A patent/KR102129412B1/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006176508A (en) | 2004-12-21 | 2006-07-06 | Golden Biotechnology Corp | Composition for inhibiting growth of prostate cancer cell and method for formulation the same |
| CN102240344B (en) | 2011-07-04 | 2013-01-09 | 辅仁药业集团有限公司 | Radix astragali capsule for treating cerebral ischemia |
| JP2017039689A (en) * | 2015-08-18 | 2017-02-23 | ゴールデン バイオテクノロジー コーポレーション | Add-on treatment of benign prostatic hyperplasia |
| CN107137571A (en) | 2017-04-05 | 2017-09-08 | 吴忠市仁爱医院有限公司 | A kind of Chinese medicine composition for treating prostatitis and hypertrophy of the prostate |
Non-Patent Citations (2)
| Title |
|---|
| Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase, Scientific Reports, 6:31906(2016.08.23.) 1부.* |
| SCIENTIFIC REPORTS. 2016 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190088201A (en) | 2019-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101144991B1 (en) | Pharmaceutical composition and health improving food composition containing ginseng extracts for preventing or treating benign postatic hyperplasia | |
| KR102567235B1 (en) | Composition for the prevention and treatment of Inflammatory Bowl Disease | |
| KR101189108B1 (en) | A composition containing dendropanax morbifera extract for improving sexual function | |
| US10130668B2 (en) | Composition comprising Dendropanax morbifera extract or compound derived therefrom as active ingredient for preventing and treating benign prostatic hyperplasia | |
| JP6545185B2 (en) | Composition for prevention, treatment and amelioration of urination disorder comprising indian pepper pepper extract | |
| KR20170121532A (en) | Composition for relieving menopausal symptom or osteoporosis | |
| KR20140098491A (en) | Mixture extract of yacon(Smallanthus sonchifolius), Torilis japonica and Acorus gramineus, health food composition and cosmetic composition for preventing or improving benign prostatic hyperplasia or alopecia containing the same | |
| KR102129412B1 (en) | Composition for preventing, improving or treating benign prostatic hyperplasia | |
| KR101698869B1 (en) | A composition for treatment of Atopic dermatitis containing oriental medicine herbs | |
| KR101919161B1 (en) | Composition for improving condition of hair and preventing hair loss | |
| US11123388B2 (en) | Composition for preventing and treating inflammatory bowel disease | |
| KR20200091925A (en) | Composition comprising a horse chestnut extract | |
| TW201221136A (en) | Treatment of varicose veins, hemorrhoids, hemorrhoids varicose veins organization, slow down the aging, skin whitening herbal extract concentrated composition | |
| KR102634898B1 (en) | Composition for the prevention and treatment of inflammatory bowl disease comprising extract of Bupleurum falcatum Linne, Cimicifuga heracleifolia, Paeonia lactiflora and Aucklandia lappa Decne | |
| KR102157247B1 (en) | A composition for improving, preventing and treating of pruritus comprising Porphyra yezoensis extract | |
| US11278748B2 (en) | Endothelin-converting enzyme inhibitor | |
| EP3721891A1 (en) | Herbal composition for preventing or treating benign prostatic hyperplasia disease | |
| KR20150040068A (en) | A pharmaceutical comprising eclipta prostrata for treating of preventing colitis | |
| KR20150110949A (en) | A composition for preventing, treating and improving of voiding disorder comprising herbal extract | |
| KR102506493B1 (en) | Composition for preventing or treating edema comprising Prasiola japonica extract or fraction thereof as active ingredient | |
| KR102453634B1 (en) | Composition for the prevention or treatment of inflammatory bowel disease comprising Zizyphus jujuba mill extract | |
| KR102376521B1 (en) | Composition for preventing, improving or treating prostate disease comprising extract of Ainsliaea acerifolia as effective component | |
| KR102376510B1 (en) | Composition for preventing, improving or treating prostate disease comprising extract of Allium macrostemom Bunge as effective component | |
| KR102496864B1 (en) | Anti-obesity composition containing extract of Paliurus ramosissimus as an active ingredient | |
| KR102380248B1 (en) | Pharmaceutical composition for the prevention and treatment of benign prostatic hyperplasia, comprising extract of Rosa laevigata Michx. and Cinnamomum cassia (L.) J.Presl |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right |